The Journal of Infectious Diseases · 1991 · 123 citations · 9 references
MedicineInfectious DiseasesPharmacologyImmunology Of Infectious DiseasesImmunopharmacologyInfectious Disease PharmacotherapyAntiretroviral TherapyAntiviral AgentsAntiviral ImmunityAntiviral PharmacologyAntiviral TherapyPost-exposure ProphylaxisHiv Antiretroviral TherapyHiv InfectiousnessHiv Postexposure ProphylaxisHiv-associated ImmunosuppressionPost-exposure Antiviral Therapy
Occupational exposure to the human immunodeficiency virus (HIV) has led to a low but finite incidence of infection among health care providers. In such circumstances, postexposure administration of 3'-azido-3'-deoxythymidine (zidovudine; AZT) might be beneficial. To test this possibility, the SCID-hu mouse (the immunodeficient C.B-17 scid/scid mouse engrafted with human hematolymphoid organs) was treated with AZT at different times after intravenous infection with a standard dose of HIV (known to infect 100% of animals). If given within 2 h, AZT suppressed infection in all animals; if given after 2 days, no suppression was observed. At least in some animals, an AZT-sensitive phase lasted for as long as 36 h. These data support the hypothesis that prompt administration of AZT might be efficacious in suppressing acute HIV infection in humans. Further studies in the SCID-hu mouse might provide insight into treatment protocols of even greater efficacy.
9
J M McCune, Reiko Namikawa, Hideto Kaneshima et al. · Science · 1988 · 1.4K citations
Infection of the SCID-hu Mouse by HIV-1
Reiko Namikawa, Hideto Kaneshima, M Lieberman et al. · Science · 1988 · 363 citations
Suppression of mouse viraemia and retroviral disease by 3′-azido-3′-deoxythymidine
Ruth M. Ruprecht, Luke G. O'Brien, Lucia D. Rossoni et al. · Nature · 1986 · 244 citations